Jun 12, 2023 / 11:00PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay. Let's get underway. Welcome, everybody, to the afternoon session here at the Goldman Sachs 44th Annual Healthcare Conference. We are, as always, super psyched to have Merck join us. CFO, Caroline Litchfield; President of Merck Research Labs, R&D guru, fried chicken aficionado, Dean Li. So thank you both for joining us.
Lots to discuss. Last year, when you were here, we saw a stock in a great trajectory. And then I think we started this year and I had Rob on the dais and like, gosh, where do we go from here? But what an eventful year-to-date actually. And for so many of these topics that we're going to discuss, Merck has really been front and center, very much front, tip of the spear kind of stuff.
Really, we're going to discuss so many things in terms of -- it's always about capital allocation priorities, et cetera, and the strategic build, leadership. We're just coming on the heels of ASCO. Obviously, some very dynamic data. You guys are very deeply engaged with all sorts of partners and cool
Merck & Co Inc at Goldman Sachs Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers